Bioelectronics Corp Stock Cash And Equivalents
| BIEL Stock | USD 0.0003 0.0001 50.00% |
Bioelectronics Corp fundamentals help investors to digest information that contributes to Bioelectronics Corp's financial success or failures. It also enables traders to predict the movement of Bioelectronics Pink Sheet. The fundamental analysis module provides a way to measure Bioelectronics Corp's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bioelectronics Corp pink sheet.
Bioelectronics |
Bioelectronics Corp Company Cash And Equivalents Analysis
Bioelectronics Corp's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Bioelectronics Corp Cash And Equivalents | 925 |
Most of Bioelectronics Corp's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bioelectronics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Bioelectronics Corp has 925 in Cash And Equivalents. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Medical Devices industry. The cash and equivalents for all United States stocks is 100.0% higher than that of the company.
Bioelectronics Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bioelectronics Corp's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bioelectronics Corp could also be used in its relative valuation, which is a method of valuing Bioelectronics Corp by comparing valuation metrics of similar companies.Bioelectronics Corp is currently under evaluation in cash and equivalents category among its peers.
Bioelectronics Fundamentals
| Return On Asset | -0.34 | |||
| Profit Margin | (0.18) % | |||
| Operating Margin | (0.09) % | |||
| Current Valuation | 52.16 M | |||
| Shares Outstanding | 24.71 B | |||
| Price To Sales | 30.73 X | |||
| Revenue | 1.61 M | |||
| Gross Profit | 795.53 K | |||
| EBITDA | (1.36 M) | |||
| Net Income | (289.82 K) | |||
| Cash And Equivalents | 925 | |||
| Total Debt | 13.34 M | |||
| Current Ratio | 0.01 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (320.3 K) | |||
| Number Of Employees | 10 | |||
| Beta | 0.45 | |||
| Market Capitalization | 12.35 M | |||
| Total Asset | 1.11 M | |||
| Retained Earnings | (28.41 M) | |||
| Working Capital | (5.75 M) | |||
| Current Asset | 1.11 M | |||
| Current Liabilities | 6.86 M | |||
| Z Score | -43.3 |
About Bioelectronics Corp Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bioelectronics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bioelectronics Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bioelectronics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Bioelectronics Pink Sheet
Bioelectronics Corp financial ratios help investors to determine whether Bioelectronics Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bioelectronics with respect to the benefits of owning Bioelectronics Corp security.